Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Report: Health Industry Spends Upwards Of $1.4 Million A Day On Lobbyists
"In a new report released yesterday, the government watchdog group Common Cause found that major health care interests have spent upwards of $1.4 million a day to lobby Capitol Hill so far this year," the National Journal reports. This political spending amount represents a 73 percent increase since 2000. In addition, the report finds that campaign contributions to members of Congress jumped $40 million since 2000, to $94 million in the 2008 election cycle (Krigman, 6/24).
generic viagra online
Even Mildly Abnormal Blood Sugar Levels During Pregnancy Increases Risk Of Developing Type 2 Diabetes
Gestational diabetes happens in more than three per cent of pregnancies in Ontario. Usually the condition resolves itself after delivery, but many studies have shown that these women are at a very high risk for developing "regular" type 2 diabetes later in life. New research out of the Institute for Clinical Evaluative Sciences (ICES) has found that even women with mild abnormalities in their blood sugar during pregnancy, previously thought not to have any clinical significance, are 2.5 times more likely to develop type 2 diabetes compared to those who had completely normal glucose testing.
News of the day
New Health Taskforce To Spot Signs Of Violence Against Women, UK
A new taskforce of health professionals working together to spot early signs of violence and abuse against women and girls, investigate the scale of the problem and ensure victims across the NHS get the support they need was announced by Home Secretary Jacqui Smith and Health Secretary Alan Johnson.
Public Health

Pfizer's Sutent Is Recommended For Reimbursement For Gastrointestinal Stromal Tumor Patients By British Health Agency

Pfizer Inc said that the United Kingdom"s National Institute for Health and Clinical Excellence (NICE) has issued its final appraisal document (FAD) recommending reimbursement for Sutent (sunitinib malate) as a second-line treatment for patients with advanced gastrointestinal stromal tumor (GIST). This recommendation follows NICE"s recently published guidance recommending reimbursement for Sutent for the first-line treatment of advanced kidney cancer. The guidance states that Sutent is recommended for reimbursement as a treatment option for patients with advanced GIST after disease progression on or intolerance to imatinib mesylate, and who have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.* According to NICE, "the benefits seen in time to tumor progression and progression free survival were such that a substantial improvement in overall survival with sunitinib treatment was probable." "NICE"s decision gives hope to patients with GIST who develop resistance to imatinib," said Dr. Mace Rothenberg, senior vice president, clinical development and medical affairs, Pfizer"s Oncology Business Unit. "Insights into the causative pathways involved with cancers like GIST will help us bring Sutent to the right patient at the right time." NICE"s decision was based on data from a pivotal Phase 3 trial of Sutent compared with placebo in patients with advanced GIST. Sutent increased time to tumor progression in the study by almost five months (6.4 weeks vs. 27.3 weeks, P About Advanced Gastrointestinal Stromal Tumor Gastrointestinal stromal tumor (GIST) is found in the gastrointestinal (GI) tract and belongs to a group of rare cancers called soft tissue sarcomas. Sarcomas begin in muscle, fat, fibrous tissue, blood vessels, or other supporting tissue of the body. Advanced GIST affects approximately 90 to 150 people in the U.K. each year, with an annual worldwide incidence of approximately 1.5 cases per 100,000 persons. Important SUTENT® (sunitinib malate) Safety Information Women of child bearing age who are (or become) pregnant during therapy should be informed of the potential for fetal harm while on SUTENT. Decreases in left ventricular ejection fraction (LVEF) to below the lower limit of normal (LLN) have been observed. Patients with concomitant cardiac conditions should be carefully monitored for clinical signs and symptoms of congestive heart failure. Patients should be monitored for hypertension and treated as needed with standard antihypertensive therapy. CBCs with platelet count and serum chemistries should be performed at the beginning of each treatment cycle for patients receiving treatment with SUTENT. The most common adverse reactions in clinical trials were fatigue, asthenia, diarrhea, nausea, mucositis/stomatitis, vomiting, dyspensia, abdominal pain, constipation, hypertension, rash, hand-foot syndrome, skin discoloration, altered taste, anorexia and bleeding. For more information on SUTENT and Pfizer Oncology, including full prescribing information for SUTENT (sunitinib malate), please visit http://www.pfizer.com. About Pfizer Oncology Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options for cancer patients worldwide. Our robust pipeline consists of 21 biologics and small molecules in clinical development across four scientific platforms - anti-angiogenesis, signal transduction, immuno-oncology, and cytotoxic potentiators. Pfizer Oncology has over 200 clinical trials including robust Phase 3 clinical trial programs in renal cell carcinoma, prostate cancer, non-small cell lung cancer, metastatic breast cancer, colorectal cancer, and hepatocellular carcinoma. By working collaboratively with academic institutions, researchers, governments, and licensing partners, Pfizer Oncology strives to transform treatment by targeting the right drug for the right patient at the right time. For more information please visit http://www.pfizer.com. Pfizer Inc: Working together for a healthier world™ Founded in 1849, Pfizer is the world"s premier biopharmaceutical company taking new approaches to better health. We discover, develop, manufacture and deliver quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. We also partner with healthcare providers, governments and local communities around the world to expand access to our medicines and to provide better quality health care and health system support. At Pfizer, more than 80,000 colleagues in more than 90 countries work every day to help people stay happier and healthier longer and to reduce the human and economic burden of disease worldwide. *Patients without symptoms or only mildly symptomatic from their cancer. Pfizer


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009